New Results
Disrupted in Renal Carcinoma 3 (DIRC3) impacts malignant phenotype and IGFBP5/IGF-1/Akt signaling axis in differentiated thyroid cancer
View ORCID ProfilePiotr T. Wysocki, View ORCID ProfileKarol Czubak, View ORCID ProfileAnna A. Marusiak, View ORCID ProfileMonika Kolanowska, View ORCID ProfileDominika Nowis
doi: https://doi.org/10.1101/2023.01.24.525402
Piotr T. Wysocki
1Laboratory of Experimental Medicine, Medical University of Warsaw, Nielubowicza 5, 02-097 Warsaw, Poland
2Department of Oncology, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland
Karol Czubak
1Laboratory of Experimental Medicine, Medical University of Warsaw, Nielubowicza 5, 02-097 Warsaw, Poland
Anna A. Marusiak
3Laboratory of Molecular OncoSignalling, IMol Polish Academy of Sciences, Flisa 6, 02-247 Warsaw, Poland
Monika Kolanowska
4Warsaw Genomics INC, Łowicka 35, 02-502 Warsaw, Poland
Dominika Nowis
1Laboratory of Experimental Medicine, Medical University of Warsaw, Nielubowicza 5, 02-097 Warsaw, Poland
5Department of Immunology, Medical University of Warsaw, Nielubowicza 5, 02-097 Warsaw, Poland
Posted January 24, 2023.
Disrupted in Renal Carcinoma 3 (DIRC3) impacts malignant phenotype and IGFBP5/IGF-1/Akt signaling axis in differentiated thyroid cancer
Piotr T. Wysocki, Karol Czubak, Anna A. Marusiak, Monika Kolanowska, Dominika Nowis
bioRxiv 2023.01.24.525402; doi: https://doi.org/10.1101/2023.01.24.525402
Subject Area
Subject Areas
- Biochemistry (11752)
- Bioengineering (8752)
- Bioinformatics (29200)
- Biophysics (14974)
- Cancer Biology (12096)
- Cell Biology (17411)
- Clinical Trials (138)
- Developmental Biology (9421)
- Ecology (14182)
- Epidemiology (2067)
- Evolutionary Biology (18308)
- Genetics (12245)
- Genomics (16803)
- Immunology (11869)
- Microbiology (28097)
- Molecular Biology (11594)
- Neuroscience (60969)
- Paleontology (451)
- Pathology (1871)
- Pharmacology and Toxicology (3238)
- Physiology (4959)
- Plant Biology (10427)
- Synthetic Biology (2886)
- Systems Biology (7340)
- Zoology (1651)